Medicare人群中转甲状腺素蛋白心脏淀粉样变诊断的及时性
本研究基于2016至2022年美国Medicare按服务付费数据,纳入7770例心衰合并ATTR-CM患者,分析从首次心衰诊断到ATTR-CM诊断的时间及延迟诊断预测因素。中位间隔494天,女性及合并主动脉瓣狭窄、冠心病、糖尿病、高血压或慢阻肺者延迟诊断风险更高。
要点
- 心衰至ATTR-CM诊断中位间隔494天,延迟显著。
- 女性及合并主动脉瓣狭窄、冠心病、糖尿病、高血压、慢阻肺者延迟风险更高。
- 对存在其他心肌病或心衰症状病因者应提高ATTR-CM警惕。
核心结论
- 心衰新发至ATTR-CM诊断存在显著延迟。
- 女性及合并主动脉瓣狭窄、冠心病、糖尿病、高血压或慢阻肺与延迟诊断相关。
研究设计与样本
- 纳入心衰且ATTR-CM诊断(心衰后或心衰前1年内)的Medicare按服务付费受益人,共7770例。
主要发现
- ATTR-CM诊断时中位年龄81岁(IQR 76-86),男性5995例(77%)。
- 心衰诊断至ATTR-CM诊断中位时间494天(IQR 63-1340)。
- 6175例在ATTR-CM诊断前有袢利尿剂处方者,首次袢利尿剂处方至ATTR-CM诊断中位时间840天(IQR 252-1768)。
- 多因素校正后,年龄较大(OR 0.68;95%CI 0.63-0.74)、房颤史(OR 0.39;95%CI 0.33-0.49)、腕管综合征(OR 0.85;95%CI 0.74-0.97)与延迟诊断几率降低相关。
- 女性(OR 1.28;95%CI 1.13-1.45)、主动脉瓣狭窄史(OR 1.39;95%CI 1.20-1.62)、慢阻肺(OR 1.18;95%CI 1.03-1.34)、冠心病(OR 1.26;95%CI 1.13-1.40)、糖尿病(OR 1.21;95%CI 1.07-1.37)、高血压(OR 1.28;95%CI 1.13-1.45)与延迟诊断几率升高相关。
关键数值与推荐
- 延迟诊断定义为心衰诊断至ATTR-CM诊断超过6个月。
临床怎么用
- 对心衰患者合并主动脉瓣狭窄、冠心病、糖尿病、高血压或慢阻肺等可致心肌病或呼吸困难病因时,应提高ATTR-CM诊断警惕。
- 女性心衰患者也应考虑ATTR-CM可能,避免延迟诊断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Timely diagnosis of transthyretin cardiac amyloidosis (ATTR-CM) is critical for early treatment to reduce morbidity and mortality, yet the timeliness of contemporary ATTR-CM diagnosis remains poorly understood. OBJECTIVE: To describe the time from incident heart failure (HF) diagnosis to ATTR-CM diagnosis and identify predictors of delayed diagnosis among Medicare beneficiaries. DESIGN, SETTING, AND PARTICIPANTS: This was a cohort study using US Medicare fee-for-service data from January 2016 to December 2022. Medicare fee-for-service beneficiaries with HF and ATTR-CM were included. Data were analyzed from November 2024 to July 2025. EXPOSURES: HF diagnosis with ATTR-CM diagnosis following HF diagnosis or within 1 year prior. MAIN OUTCOMES AND MEASURES: The primary outcome was time to ATTR-CM diagnosis, measured as the number of days between each patient's first HF diagnosis and first ATTR-CM diagnosis. Multivariable logistic regression assessed demographic, clinical, and socioeconomic factors associated with delayed ATTR-CM diagnosis (defined as >6 months from HF diagnosis to ATTR-CM diagnosis). RESULTS: A total of 7770 patients with HF and ATTR-CM were identified in the Medicare dataset. The median (IQR) age at the time of ATTR-CM diagnosis was 81 (76-86) years; 5995 enrollees (77%) were men. The median (IQR) time from HF diagnosis to ATTR-CM diagnosis was 494 (63-1340) days. For the 6175 patients with a loop diuretic prescription before ATTR-CM diagnosis, the median (IQR) time between initial loop prescription and ATTR-CM diagnosis was 840 (252-1768) days. After adjustment, older age (odds ratio [OR], 0.68; 95% CI, 0.63-0.74), history of atrial fibrillation (OR, 0.39; 95% CI, 0.33-0.49), and carpal tunnel syndrome (OR, 0.85; 95% CI, 0.74-0.97) were associated with lower odds of delayed diagnosis. Female sex (OR, 1.28; 95% CI, 1.13-1.45), a history of aortic stenosis (OR 1.39; 95% CI, 1.20-1.62), chronic obstructive pulmonary disease (OR, 1.18; 95% CI, 1.03-1.34), coronary artery disease (OR, 1.26; 95% CI, 1.13-1.40), diabetes (OR, 1.21; 95% CI, 1.07-1.37), and hypertension (OR, 1.28; 95% CI, 1.13-1.45) were associated with higher odds of delayed diagnosis. CONCLUSIONS AND RELEVANCE: There were substantial delays between incident HF and diagnosis of ATTR-CM found in this study. Female sex and having a history of aortic stenosis, coronary artery disease, diabetes, hypertension, or chronic obstructive pulmonary disease, which are each associated with cardiomyopathy and breathlessness, were associated with delayed diagnosis. These findings highlight the need for a heightened index of suspicion for ATTR-CM in patients with other possible etiologies of cardiomyopathy or HF symptoms.
引用
- Spencer-Bonilla G, Fan J, Cheng P, et al. Timeliness of Transthyretin Cardiac Amyloidosis Diagnosis in the Medicare Population. JAMA Cardiol. 2026. PMID: 42054052. doi:10.1001/jamacardio.2026.0833
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。